Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety chargesBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3536 (Published 30 May 2013) Cite this as: BMJ 2013;346:f3536
- Meera Kay
Generic drug manufacturer Ranbaxy has agreed to pay a fine of $500m (£330m; €385m) to settle US government charges of fraud at two of its Indian factories, which came to light eight years ago. The fine is the largest ever in US history to be paid by a generic manufacturer over drug safety.
Ranbaxy USA, a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories, will pay a criminal fine and forfeiture of $150m, plus $350m to settle civil claims brought by the federal government and all 50 US states.
US Food and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial